External request:
Submission from Genentech Inc (08/15/19) to review and consider data for and recommend entrectinib and appropriate NTRK gene fusion testing for the treatment of NTRK gene fusion-positive melanoma.

Based on a review of data from the submission, the panel vote supported changing the guidelines as follows: “Larotrectinib or entrectinib for NTRK gene fusion positive tumors” as a second-line or subsequent systemic therapy option for metastatic or unresectable disease. This recommendation has been preference stratified as “Useful In Certain Circumstances.” Information regarding the NTRK gene fusion testing in melanoma was added to the Principles of Molecular Testing section (ME-C) in a previous version update.

References: